BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borchiellini D, Barthélémy P. Cabozantinib: a new first-line option for papillary renal cell carcinoma? Lancet 2021;397:645-7. [PMID: 33592177 DOI: 10.1016/S0140-6736(21)00316-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Kanesvaran R, Porta C, Wong A, Powles T, Ng QS, Schmidinger M, Ye D, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Bhattacharyya GS, Curigliano G, Poon E, Choo SP, Peters S, Lim E, Yoshino T, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO Open 2021;6:100304. [PMID: 34864348 DOI: 10.1016/j.esmoop.2021.100304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]